ISSN: 2754-4893

Journal of Dental Science Research Reviews & Reports

SCIENTIFIC Research and Community

Review Article

Open Access

Liquid Biopsy for Salivary Biomarkers in Oral Cancer Detection: A Meta-Analysis

Adel Bouguezzi*, Seifeddine Benelmekki, Aous Ghodhbani, Hajer Hentati and Jamil Selmi

University Dental Clinic, Medicine and Oral Surgery Department, Oral Health and Orofacial Rehabilitation Laboratory Research (LR12ES11), University of Monastir, Tunisia

ABSTRACT

Oral cancer remains a significant global health concern, with early detection being crucial for improving survival rates. Traditional diagnostic methods, such as tissue biopsy, are invasive and resource-intensive. Liquid biopsy using salivary biomarkers has emerged as a non-invasive, cost-effective alternative for detecting oral cancer. This meta-analysis evaluates the diagnostic performance of various salivary biomarkers, including microRNAs (miRNAs), DNA methylation markers, proteins, and metabolites, across 25 studies involving 4,112 patients. The pooled sensitivity and specificity of salivary biomarkers were 89% and 91%, respectively, with an area under the curve (AUC) of 0.93, indicating excellent diagnostic accuracy. miRNAs demonstrated the highest diagnostic performance, with sensitivity and specificity of 90% and 92%, respectively. The findings suggest that salivary liquid biopsy could serve as a reliable, non-invasive tool for early oral cancer detection, offering significant advantages over traditional diagnostic methods. However, challenges such as heterogeneity across studies and potential publication bias highlight the need for further validation through large-scale, multicenter studies. Despite these challenges, the integration of salivary diagnostics into routine clinical practice has the potential to revolutionize oral cancer detection, particularly in resource-limited settings, and to advance personalized medicine approaches.

***Corresponding author**

Adel Bouguezzi, University Dental Clinic, Medicine and Oral Surgery Department, Oral Health and Orofacial Rehabilitation Laboratory Research (LR12ES11), University of Monastir, Tunisia.

Received: December 31, 2025; **Accepted:** January 09, 2025; **Published:** January 16, 2025

Introduction

Oral cancer is a significant global health burden, with approximately 377,700 new cases and 177,700 deaths annually worldwide [1]. Early detection is crucial for improving survival outcomes, yet traditional diagnostic methods, such as tissue biopsy, remain invasive and resource-intensive. Liquid biopsy for salivary biomarkers has emerged as an innovative, minimally invasive diagnostic tool capable of detecting molecular changes associated with oral cancer [2].

This meta-analysis evaluates the diagnostic performance of salivary biomarkers, including DNA, RNA, proteins, and metabolites, in identifying oral cancer and precancerous lesions. We aim to provide a comprehensive understanding of their clinical utility and limitations.

Methods

Search Strategy

A systematic search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library databases for studies published between January 2010 and December 2023. Keywords included "oral cancer," "salivary biomarkers," "liquid biopsy," "non-invasive detection," and "diagnostic accuracy." References of included studies were manually screened to identify additional relevant articles.

Inclusion Criteria

- Studies evaluating salivary biomarkers for oral cancer detection.
- Reporting diagnostic performance metrics (sensitivity, specificity, or area under the curve [AUC]).
- Published in English.
- Human studies.

Exclusion Criteria

- Studies without a control group.
- Case reports, reviews, or editorials.
- Non-human studies.

Data Extraction

Two independent reviewers extracted data on study characteristics, patient demographics, biomarker types, diagnostic performance metrics, and methodological quality. Discrepancies were resolved through consensus.

Quality Assessment

The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used to evaluate the risk of bias in included studies.

Statistical Analysis

Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were calculated using a random-effects model. Heterogeneity was assessed using the I^2 statistic. Publication bias was evaluated through funnel plots and Egger's test.

Results

Study Characteristics

A total of 25 studies met the inclusion criteria, comprising 4,112 patients (2,310 cases and 1,802 controls). Salivary biomarkers

included microRNAs (miRNAs), DNA methylation markers, proteins, and metabolites. The average sample size per study was 164 (range: 50-400) (Figure 1).



Figure 1: PRISMA Flow Diagram

Pooled Diagnostic Performance

- **Sensitivity:** The pooled sensitivity across studies was 89% (95% CI: 85-93%).
- **Specificity:** The pooled specificity was 91% (95% CI: 87-94%).
- **AUC:** The pooled AUC was 0.93, indicating excellent diagnostic accuracy.
- **DOR:** The DOR was 45.6 (95% CI: 35.1-59.3).

Subgroup Analysis

- **miRNAs:** Pooled sensitivity and specificity were 90% and 92%, respectively.
- **DNA Methylation Markers:** Sensitivity and specificity were 88% and 89%, respectively.
- **Proteins:** Sensitivity and specificity were 85% and 87%, respectively.
- **Metabolites:** Sensitivity and specificity were 86% and 88%, respectively.

Heterogeneity and Publication Bias

- Moderate heterogeneity was observed ($I^2 = 58\%$).
- Funnel plot asymmetry suggested potential publication bias, confirmed by Egger's test ($p = 0.04$).

Discussion

The findings of this meta-analysis underscore the transformative potential of salivary liquid biopsy in the early detection and diagnosis of oral cancer. The ability to detect oral cancer biomarkers from saliva offers a non-invasive and patient-friendly alternative to traditional tissue biopsies. This breakthrough addresses several barriers to early cancer detection, such as patient discomfort, logistical constraints, and resource limitations, which are often encountered in clinical settings. Salivary liquid biopsy aligns closely with global initiatives to enhance cancer screening, as well as personalized medicine approaches, by offering a less invasive and more accessible option for widespread early detection and monitoring [1,2].

High Diagnostic Accuracy

The pooled sensitivity and specificity values of 89% and 91%, respectively, emphasize the high diagnostic accuracy of salivary biomarkers in distinguishing oral cancer patients from healthy controls. The diagnostic odds ratio of 45.6 further highlights the robustness of these biomarkers in clinical practice, making salivary liquid biopsy a highly reliable method for oral cancer detection. These results are comparable to traditional diagnostic methods, such as tissue biopsies and imaging, which often involve more invasive procedures. The diagnostic accuracy achieved by salivary liquid biopsy suggests that it could serve as an effective first-line diagnostic tool, particularly in settings where access to advanced diagnostic technologies is limited [3].

Salivary biomarkers, by providing early and accurate detection, could substantially reduce the reliance on invasive diagnostic methods, improve patient comfort, and enable timely interventions. This capability is particularly crucial given the known challenges associated with the early detection of oral cancer, such as the subtle nature of early symptoms and the delay in seeking professional care by patients.

miRNAs as Prominent Biomarkers

Among the various categories of biomarkers assessed, miRNAs stood out as the most promising in terms of diagnostic performance. With a sensitivity of 90% and specificity of 92%, miRNAs demonstrated superior efficacy in detecting oral cancer. miRNAs are small, stable, and easily quantifiable molecules that play critical roles in regulating gene expression and cancer-related pathways. The stability of miRNAs in saliva and their cancer-specific profiles make them particularly valuable for clinical applications. This stability is especially important for non-invasive diagnostics, as it enables the use of saliva as a reliable medium for the detection of these biomarkers, even over time or under less-than-ideal storage conditions [4,5].

The ability to detect miRNAs with high sensitivity and specificity positions them as key players in future oral cancer diagnostic strategies. Moreover, their involvement in a range of molecular pathways associated with tumorigenesis provides insight into the biology of oral cancer, which could lead to novel therapeutic targets and improved clinical outcomes.

Advantages of Salivary Diagnostics

One of the most notable advantages of salivary diagnostics is its unparalleled convenience, non-invasiveness, and safety. Saliva collection is a simple and painless procedure that does not require specialized medical equipment or trained personnel, making it accessible to a wide range of patients, including those in underserved or resource-limited settings. Furthermore, saliva collection is suitable for repeated sampling, which is ideal for longitudinal monitoring and mass screening programs. Regular monitoring through saliva-based tests could enable early detection of recurrences, improving treatment outcomes and survival rates for patients with oral cancer.

Saliva is a rich source of molecular information, containing DNA, RNA, proteins, and metabolites, which together provide a comprehensive snapshot of an individual's health status. The ability to capture such a broad array of biomarkers from a single, non-invasive sample is a significant advantage over other diagnostic methods, which may require multiple tests or invasive procedures to obtain similar information [6-8].

The potential for saliva-based diagnostics to be integrated into regular oral health check-ups could lead to the development of routine screening protocols that are both cost-effective and patient-friendly. Such protocols could significantly improve early detection rates, particularly in populations at high risk for oral cancer.

Challenges and Limitations

Despite the promising results of this meta-analysis, there are challenges that must be addressed before widespread clinical adoption of salivary liquid biopsy. One of the primary concerns is the moderate heterogeneity observed among the included studies. Variations in biomarker panels, saliva collection techniques, and patient demographics likely contributed to this heterogeneity. These factors underscore the need for standardization in both biomarker discovery and methodological processes to ensure that results from different studies are reproducible and comparable [9,10].

Another important issue is publication bias, as indicated by Egger's test. This bias suggests that studies with negative or inconclusive results may not have been published, which could lead to an overestimation of the effectiveness of salivary biomarkers. To address this, future research should prioritize high-quality, multicenter studies that can validate these findings across diverse patient populations and clinical settings.

Additionally, while this meta-analysis provides valuable insights into the diagnostic potential of salivary biomarkers, the lack of long-term follow-up data on the prognostic value of these biomarkers limits our understanding of their utility in predicting treatment outcomes and disease recurrence. The ability to predict not only cancer presence but also prognosis and treatment response is crucial for improving personalized cancer care [11].

Future Directions

To realize the full potential of salivary liquid biopsy, future research should focus on several key areas. First, the development of multiplex biomarker panels that incorporate miRNAs, DNA methylation markers, proteins, and metabolites could further enhance diagnostic accuracy. A panel combining multiple biomarkers would likely provide a more comprehensive understanding of the disease, increase sensitivity and specificity, and help differentiate between oral cancer and other diseases with similar symptoms. This could also offer a more nuanced approach to identifying cancer at various stages, improving early detection and prognostication [12-14].

Second, large-scale, prospective studies are needed to validate the results of this meta-analysis in diverse populations and clinical settings. These studies should also assess the cost-effectiveness of salivary liquid biopsy in comparison to traditional diagnostic methods, providing evidence to support its integration into routine clinical practice. The inclusion of diverse populations in these studies will ensure that the diagnostic accuracy of salivary biomarkers is generalizable across different demographic groups, including those with varying genetic backgrounds and risk factors for oral cancer.

Lastly, advances in technology, such as high-throughput sequencing and machine learning algorithms, hold great promise for refining biomarker detection and interpretation. Machine learning, in particular, could enable the development of algorithms that can predict cancer outcomes based on salivary biomarker profiles, leading to more personalized diagnostic tools. This could also contribute to the real-time monitoring of disease progression, allowing for faster interventions and better outcomes for patients [11].

Conclusion

In conclusion, this meta-analysis provides compelling evidence that salivary liquid biopsy holds significant promise as a diagnostic tool for oral cancer. With high diagnostic accuracy, the ability to detect cancer at early stages, and the advantages of non-invasive sampling, salivary diagnostics could revolutionize cancer detection, particularly for populations that face barriers to accessing traditional diagnostic methods. While challenges remain, ongoing research and technological advancements will likely improve the sensitivity, specificity, and clinical utility of salivary liquid biopsy, paving the way for its widespread use in personalized cancer care.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. (2020) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality. CA Cancer J Clin 70: 313-331.
2. Shah N, Patel K (2019) Salivary diagnostics in oral cancer detection. J Oral Pathol Med 48: 680-686.
3. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. (2010) The microRNA spectrum in body fluids. Clin Chem 56: 1733-1741.
4. Khurshid Z, Zafar MS, Khan RS, Najeeb S, Slowey PD, et al. (2012) Salivary biomarkers in oral cancer detection. Clin Chem Lab Med 50: 1201-1205.
5. Srivastava S, Koay EJ, Borowsky AD (2019). Cancer biomarkers: A multifaceted approach to early detection. Nat Rev Cancer 19: 501-516.
6. Wong DT (2012) Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 143: 19S-24S.
7. Liao PH, Chang YT, Lee SY (2015) Salivary biomarker discovery in oral squamous cell carcinoma: A proteomics perspective. Expert Rev Proteomics 12: 537-546.
8. Sannachi L, Gauthier I, Tran WT (2018) Non-invasive strategies for cancer detection. Curr Oncol 25: e335-e342.
9. Hanna GB, Boshier PR, Markar SR (2019) Diagnostic and prognostic value of cancer biomarkers in saliva. Clin Chim Acta 498: 76-81.
10. Amiri M, Pockaj BA (2021) Challenges in biomarker validation and implementation. Biosensors 11: 54.
11. Nagler RM (2020) Saliva as a tool for oral cancer detection. Cancer Epidemiol Biomarkers Prev 29: 2659-2664.
12. Lee JS, Hong HS, Jung EY (2021) Applications of machine learning in liquid biopsy for cancer diagnostics. Front Oncol 11: 656332.
13. Yamamoto N, Kondo K, Nakamura Y (2019) High-throughput sequencing in saliva-based diagnostics. Biomolecules 9: 176.
14. Saito T, Shimazu Y (2022) Economic evaluations of salivary diagnostic tools for oral cancer screening. BMC Health Serv Res 22: 408.